Integrative proteogenomics for differential expression and splicing variation in a DM1 mouse model.
Proteogenomics
alternative splicing
myotonic dystrophy type 1 (DM1)
Journal
Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
received:
31
07
2022
revised:
02
09
2023
accepted:
17
11
2023
medline:
23
11
2023
pubmed:
23
11
2023
entrez:
22
11
2023
Statut:
aheadofprint
Résumé
Dysregulated mRNA splicing is involved in the pathogenesis of many diseases including cancer, neurodegenerative diseases, and muscular dystrophies such as myotonic dystrophy type 1 (DM1). Comprehensive assessment of dysregulated splicing on the transcriptome and proteome level has been methodologically challenging, and thus investigations have often been targeting only few genes. Here, we performed a large-scale coordinated transcriptomic and proteomic analysis to characterize a DM1 mouse model (HSA
Identifiants
pubmed: 37993104
pii: S1535-9476(23)00194-9
doi: 10.1016/j.mcpro.2023.100683
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100683Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest All authors are employees of Novartis, and some hold Novartis stock.